Related Experiment Videos
Abstract:
The need for clinical monitoring to assure drug safety despite reliance on Food and Drug Administration testing is illustrated. The need to temper theory with clinical experience is exemplified by the recent examples of swine flu, resistant gonorrhea, and resistant pneumococcal infection. The potential for adverse effects to escape detection in animal studies and small-scale human trials is illustrated by the examples of ticrynafen, chloramphenicol, and diethylstilbestrol. The potential for unexpected side effects when established drugs are used in new ways is demonstrated by the examples of retrolental fibroplasia and vitamin D toxicity. The responsibilities of the medical profession and the individual practitioner include a healthy skepticism of newly introduced treatments, active participation in clinical monitoring, and maintenance of a system for chart retrieval when drugs are recalled or new effects reported.
Insights
Post-market surveillance is crucial for drug safety, as clinical monitoring can reveal issues missed by initial FDA testing. Medical professionals must remain skeptical and actively participate in monitoring for patient well-being.
Area of Science:
- Pharmacovigilance
- Clinical Medicine
- Drug Safety
Background:
- Regulatory agencies like the Food and Drug Administration (FDA) conduct pre-market testing, but limitations exist.
- Clinical experience and monitoring are essential to complement theoretical data and regulatory testing.
- Historical examples highlight the importance of ongoing drug safety evaluation.
Purpose of the Study:
- To underscore the necessity of continuous clinical monitoring for ensuring drug safety.
- To illustrate the limitations of pre-market testing in detecting all potential adverse effects.
- To emphasize the role of healthcare professionals in post-market drug surveillance.
Main Methods:
- Review of historical drug safety incidents and adverse event reports.
- Analysis of cases where clinical experience revealed issues missed in initial trials.
- Examination of examples demonstrating unexpected side effects in new drug applications and established drug uses.
Main Results:
- Clinical monitoring identified safety issues not detected by FDA testing, as seen with swine flu vaccines and resistant infections.
- Adverse effects were missed in animal studies and small human trials for drugs like ticrynafen and chloramphenicol.
- Established drugs used in novel ways led to unexpected side effects, exemplified by retrolental fibroplasia and vitamin D toxicity.
Conclusions:
- Clinical monitoring is indispensable for drug safety, supplementing regulatory oversight.
- Healthcare providers must exercise skepticism towards new treatments and actively engage in monitoring.
- Effective chart retrieval systems are vital for managing drug recalls and reported adverse effects.